Product and Pipeline Analysis of the Global Rheumatoid Arthritis Therapeutics Market

Launch of Novel Oral Therapies to Result in Major Market Changes

Regular Price: USD 3,950.00

Special Price USD 3,555.00

10% OFF

* Required Fields

Regular Price: USD 3,950.00

Special Price USD 3,555.00


Be the first to review this product

This market insight discusses the rheumatoid arthritis pharmaceutical drugs currently in the global market as well as those in the development stage. It offers a competitive analysis of the drugs and a forecast of their impact on the market. Drugs in the development stage are segmented by clinical trial phase as well as by drug class. The study covers profiles of late-stage investigational products close to being launched, patent expiration timelines, products in clinical development, launched product profiles, and new product launch timelines.

Table of Contents

Executive SummaryKey FindingsKey Findings (continued)Companies to WatchDefining Healthcare Trends in the FutureExecutive Summary—CEO’s PerspectiveMarket OverviewMarket Overview—DefinitionsMarket Overview—Definitions (continued)Market Overview—Definitions (continued)Market Overview—Definitions (continued)Market Overview—Definitions (continued)Market Overview—Definitions (continued)Market Overview—Segmentation Market Overview—Segmentation (continued) Market Overview—Segmentation (continued) Rheumatoid Arthritis Global IncidenceExternal Challenges: Drivers and Restraints—Total Rheumatoid Arthritis Therapeutics MarketDrivers and RestraintsCompetitive Analysis—Total Rheumatoid Arthritis Therapeutics MarketCompetitive Factors and AssessmentCompetitive Landscape—Count of Marketed and Pipeline ProductsCompetitive Landscape—Marketed and Pipeline ProductsMarketed Product Analysis Marketed Product Analysis (continued) Patent Expiration TimelinePipeline Analysis—Products in Clinical DevelopmentPipeline Analysis—Products in Clinical Development (continued)Pipeline Analysis—Products in Clinical Development (continued)Product Launch TimelinePhase 3 Clinical Program—Next Product LaunchesProfiles of Late-stage Investigational Products Close to be LaunchedProduct Dashboard—Eli Lilly’s BaricitinibProduct Dashboard—Sanofi/Regeneron’s SAR153191/REGN88Product Dashboard—Biocad’s BCD-020The Last WordThe Last Word—Three Big PredictionsThe Last Word—DiscussionLegal DisclaimerAppendixMarket Engineering MethodologyTable of Acronyms UsedTable of Acronyms Used (continued)Table of Acronyms Used (continued)Drivers ExplainedDrivers Explained (continued)Drivers Explained (continued)Drivers Explained (continued)Restraints ExplainedRestraints Explained (continued)Additional Sources of Information on Rheumatoid ArthritisAdditional Sources of Information on Rheumatoid Arthritis (continued)Learn More—Next StepsThe Frost & Sullivan StoryThe Frost & Sullivan StoryValue Proposition—Future of Your Company & CareerGlobal PerspectiveIndustry Convergence360º Research PerspectiveImplementation ExcellenceOur Blue Ocean Strategy

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.